Pixuvri
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Pixantrone dimaleate
- Made by
- Les Laboratoires Servier
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Les Laboratoires Servier |
|---|---|
| Active substance | Pixantrone dimaleate |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01DB11 · Cancer treatments and immune-system medicines |
| Authorised on | 2012-05-10 |
| Last updated by the regulator | 2024-07-10 |
| EMA product number | EMEA/H/C/002055 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).